Ziprasidone augmentation of escitalopram for major depressive disorder: Cardiac, endocrine, metabolic, and motoric effects in a randomized, double-blind, placebo-controlled study

David Mischoulon, Richard C. Shelton, Lee Baer, William V Bobo, Laura Curren, Maurizio Fava, George I. Papakostas

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Objective: To examine motoric, cardiovascular, endocrine, and metabolic effects of adjunctive ziprasidone in adults with major depressive disorder (MDD) and prior nonresponse to 8 weeks of open-label escitalopram. Methods: A multicenter, parallel, randomized, doubleblind, placebo-controlled trial was conducted at 3 US academic medical centers from July 2008 to October 2013. Recruited were 139 outpatients with persistent DSM-IV MDD following an 8-week open-label trial of escitalopram. Subjects were then randomized to adjunctive ziprasidone (escitalopram + ziprasidone, n = 71) or placebo (escitalopram + placebo, n = 68) for 8 additional weeks. Cardiac and metabolic measures were obtained at each treatment visit. Barnes Akathisia Scale and Abnormal Involuntary Movement Scale (AIMS) scores were also obtained. Changes in outcome measures for each treatment group were compared by independent-samples t test. Results: A trend toward significance (P = .06) in corrected QT interval (QTc) increase was observed for ziprasidone (mean [SD] = 8.8 [20.2] milliseconds) versus placebo (-0.02 [25.5] milliseconds). Ziprasidone-treated patients had a significantly greater increase in global akathisia scores (P = .01) and significant weight increase (mean [SD] = 3.5 [11.8] kg, or 7.7 [26.1] lb) compared to placebo (1.0 [6.4] kg, or 2.2 [14.1] lb) (P = .03). No significant changes in AIMS scores were observed for either treatment group. Conclusions: Adjunctive ziprasidone, added to escitalopram, led to a greater weight gain and greater but modest akathisia compared to placebo. The effect of ziprasidone on QTc showed a trend toward significance, and therefore caution should be used in the administration of ziprasidone. While ziprasidone augmentation in patients with MDD appears safe, precautions should be taken in practice, specifically regular monitoring of electrocardiogram, weight, extrapyramidal symptoms, and involuntary movements.

Original languageEnglish (US)
Pages (from-to)449-455
Number of pages7
JournalJournal of Clinical Psychiatry
Volume78
Issue number4
DOIs
StatePublished - Apr 1 2017

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Ziprasidone augmentation of escitalopram for major depressive disorder: Cardiac, endocrine, metabolic, and motoric effects in a randomized, double-blind, placebo-controlled study'. Together they form a unique fingerprint.

  • Cite this